Aggressive Lymphomas
News
Metabolic tumor volume predicts outcome in follicular lymphoma
Key clinical point: At diagnosis, the total metabolic tumor volume of follicular lymphoma predicts treatment response and patient outcome. Major...
Conference Coverage
Cancer trends shifting in HIV-positive patients
Key clinical point: HIV-infected persons in North America have roughly a 1 in 25 cumulative lifetime risk of developing lung cancer, Kaposi’s...
Conference Coverage
HIV-related lymphoma rate remains sky-high despite ART
DURBAN, SOUTH AFRICA – Antiretroviral therapy has had a major impact upon the incidence of HIV-related non-Hodgkin lymphoma but not Hodgkin...
News
Bendamustine-based chemotherapy induces high CR rate in relapsed HL
Key clinical point: Bendamustine in combination chemotherapy produces high response rates in relapsed refractory Hodgkin lymphoma (HL). Major...
News
Pembrolizumab shows signs of efficacy in relapsed/refractory classical Hodgkin lymphoma
Key clinical point: Pembrolizumab is a potential treatment option for relapsed/refractory classical Hodgkin lymphoma. Major finding: The complete...
Conference Coverage
‘Impressive’ responses with nivolumab in relapsed Hodgkin lymphoma
Key clinical point:.
Conference Coverage
Daratumumab plus len-dex stalls myeloma progression in POLLUX trial
The anti-CD38 monoclonal antibody daratumumab added to lenalidomide/dexamethasone improved progression-free survival in relapsed/refractory...
News
Follicular lymphoma with histologic transformation may merit ASCT
Key clinical point: Histologic transformation of follicular lymphoma tends to occur early and may merit intensive salvage with autologous stem...
Conference Coverage
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphoma
Key clinical point: The anti-CCR4 monoclonal antibody mogamulizumab was superior to other investigator-selected therapies for the treatment of...
Conference Coverage
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomas
Key clinical point: Adding the monoclonal anti-CD52 antibody alemtuzumab to CHOP (A-CHOP) increased response rates in elderly patients with...